Home  /  Resource Library  /  Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Results of a study investigating bispecific epcoritamab for treatment of relapsed large cell lymphomas.